Video

Dr. Mascarenhas on the Significance of Pacritinib in Myelofibrosis

John O. Mascarenhas, MD, discusses the potential significance of pacritinib in patients with myelofibrosis.

John O. Mascarenhas, MD, an associate professor of medicine, hematology, and medical oncology at the Icahn School of Medicine at Mount Sinai, discusses thepotentialsignificance of pacritinib in patients with myelofibrosis.

Pacritinib is an important potential agent in this patient population, as it's the 1 JAK2 inhibitor that appears to cause the least amount of myelosuppression, Mascarenhas explains, especially in relation to thrombocytopenia. Patients who have a platelet count below 50,000, defined as severe thrombocytopenia, are an unmet need within the space; the current JAK inhibitors that are approved in myelofibrosis cannot be safely administered to this patient population, he adds.

This patient population is typified by a myelodepleted phenotype. While they don't always have enlarged spleens, they are typically characterized by low blood counts and poor outcomes, Mascarenhas concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma
Video

Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma

Jun 19th 2025 - Jul 25th 2025

online-activity
Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies
Audio

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Jun 18th 2025 - Jun 19th 2026

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity